Vaxart, developer of new medical technology that will allow doctors to administer vaccines orally, has brought in $3.5 million of a targeted $12.5 million round of equity, second-round preferred stock and common stock issuable upon the conversion of preferred stock, according to a filing with the SEC. Based in San Francisco, the company in backed by Quantum Technology Partners and Life Science Angels. It previously raised a $3.3 million first round of funding in November 2007.